No drug-drug interaction between tezacaftor-ivacaftor and clofazimine: A case report.
Clofazimine is an antimycobacterial drug which is used for the treatment of non-tuberculous mycobacterium (NTM). In August 2019 clofazimine got a positive opinion for orphan designation for the treatment of NTM lung disease by the European Medicines Agency. In vitro clofazimine has been characterized as an inhibitor of cytochrome P450 (CYP)3A4/5, 2C8 and 2D6. In previously performed static and physiologically based pharmacokinetic (PBPK) modeling prediction studies an interaction between clofazimine and midazolam, a probe substrate for CYP3A4, was characterized.
Source: Journal of Cystic Fibrosis - Category: Respiratory Medicine Authors: S.E.M. Vonk, S.W.J. Terheggen-Lagro, L.M. Mouissie, R.A.A. Math ôt, E.M. Kemper, Amsterdam Mucociliary Clearance Disease (AMCD) research group Tags: Case Report Source Type: research